ASSOCIATION OF MTHFR A1298C GENE VARIANT, DNA DAMAGE, AND TOTAL ANTIOXIDANT STATUS WITH THE RISK OF TYPE 2 DIABETES MELLITUS AND ITS COMPLICATIONS
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i6.25076Keywords:
Methylenetetrahydrofolate reductase, Polymorphism, Folate metabolism, Total antioxidant status, DNA damage, Type 2 diabetes mellitusAbstract
Objectives: We have examined the association of methylenetetrahydrofolate reductase (MTHFR) gene A1298C variant, DNA damage, and total antioxidant status (TAS) in patients with type 2 diabetes mellitus (T2DM) with and without complications and in healthy controls.
Methods: A total of 300 subjects including 100 patients with complications, 100 patients without complications, and 100 controls were included. TAS was assessed by ferric reducing ability of plasma assay. DNA damage was analyzed in lymphocytes using the comet assay. Polymerase chain reaction-restriction fragment length polymorphism analysis was performed to study the MTHFR A1298C gene polymorphism among the study subjects.
Results: The results revealed that the MTHFR 1298 AC+CC genotypes were associated with increased risk (2 fold) for diabetes and its complications. When the effect of DNA damage was analyzed, significant differences between individuals with mutant and normal genotype among the diabetic patients (with and without complications) was observed (p≤0.001). In contrary, no significant difference was found between TAS and 1298 genotypes (AA vs. AC+CC) in Type 2 diabetes patients (with and without complications), p=0.338. We also found a significant difference between the genotypes of the MTHFR A1298C and DNA damage, TAS in T2DM patients (with & without complications) when compared to controls, p<0.001.
Conclusions: Our findings suggest that the MTHFR A1298C gene polymorphism is considered as a risk factor for the development of diabetes and its complications among south Indians. Therefore, increased DNA damage and decreased TAS along with the occurrence of a mutant genotype in an individual with diabetes may be at an increased risk for the development of chronic complications.
Downloads
References
Levitt NS, Bradshaw D, Zwarenstein MF, Bawa AA, Maphumolo S. Audit of public sector primary diabetes care in Cape Town, South Africa: High prevalence of complications, uncontrolled hyperglycaemia, and hypertension. Diabet Med 1997;14:1073-7.
Adak S, Sengupta S, Chowdhury S, Bhattacharyya M. Co-existence of risk and protective haplotypes of calpain 10 gene to Type 2 diabetes in the eastern Indian population. Diab Vasc Dis Res 2010;7:63-8.
Wallace JI. Management of diabetes in elderly. Clin Diabetes 2004;17:1.
van Tilburg J, van Haeften TW, Pearson P, Wijmenga C. Defining the genetic contribution of Type 2 diabetes mellitus. J Med Genet 2001;38:569-78.
Barbosa PR, Stabler SP, Machado AL, Braga RC, Hirata RD, Hirata MH, et al. Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. Eur J Clin Nutr 2008;62:1010-21.
Sukla KK, Raman R. Association of MTHFR and RFC1 gene polymorphism with hyperhomocysteinemia and its modulation by vitamin B12 and folic acid in an Indian population. Eur J Clin Nutr 2012;66:111-8.
Yakub M, Moti N, Parveen S, Chaudhry B, Azam I, Iqbal MP, et al. Polymorphisms in MTHFR, MS and CBS genes and homocysteine levels in a Pakistani population. PLoS One 2012;7:e33222.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002;99:5606-11.
Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 2000;26:219-25.
Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ, et al. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318-23.
Crott J, Fenech M. Preliminary study of the genotoxic potential of homocysteine in human lymphocytes in vitro. Mutagenesis 2001;16:213-7.
Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA methylation and atherosclerosis. J Nutr 2002;132:2406S-9S.
Wang H, Hu C, Xiao SH, Wan B. Association of tagging SNPs in the MTHFR gene with risk of Type 2 diabetes mellitus and serum homocysteine levels in a Chinese population. Dis Markers 2014;2014:725731.
Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant powerâ€: The FRAP assay. Anal Biochem 1996;239:70-6.
Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000;35:206-21.
Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-91.
Iranpur MV, Esmailizadeh AK, Horriat R, Asadi KE, Shiran B, Sorkheh K, et al. Rapid extraction of high quality DNA from whole blood stored at 4ºC for long period. Iran: Department of Animal Science, Faculty of Agriculture, Shahrekord University, Shahrekord, Protocol Online; 2002.
Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: Association with plasma total homocysteine and folate concentrations. J Nutr 1999;129:1656 61.
Hussain M, Naqvi SB, Khan MA, Rizvi M, Alam S, Abbas A, et al. Direct cost of treatment of diabetes mellitus Type 2 in Pakistan. Int J Pharm Pharm Sci 2014;6:261-4.
Andayani TM, Ibrahim MI, Asdie AH. The association of diabetes-related factor and quality of life in Type 2 diabetes mellitus. Int J Pharm Pharm Sci 2010;2:139-45.
Fekih-Mrissa N, Mrad M, Ibrahim H, Akremi I, Sayeh A, Jaidane A, et al. Methylenetetrahydrofolate reductase (MTHFR) (C677T and A1298C) polymorphisms and vascular complications in patients with Type 2 diabetes. Can J Diabetes 2017;41:366-71.
AbdRaboh NR, Badr S, Ali S. Prevalence of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Egyptian patients with Type 2 diabetes mellitus. Egypt J Med Hum Genet 2013;14:87-93.
Chang YH, Fu WM, Wu YH, Yeh CJ, Huang CN, Shiau MY, et al. Prevalence of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Taiwanese patients with Type 2 diabetic mellitus. Clin Biochem 2011;44:1370-4.
Benrahma H, Abidi O, Melouk L, Ajjemami M, Rouba H, Chadli A, et al. Association of the C677T polymorphism in the human methylenetetrahydrofolate reductase (MTHFR) gene with the genetic predisposition for Type 2 diabetes mellitus in a Moroccan population. Genet Test Mol Biomarkers 2012;16:383-7.
Sun J, Xu Y, Xue J, Zhu Y, Lu H. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese Type 2 diabetic patients. Mol Cell Endocrinol 2005;229:95 101.
Fekih-Mrissa N, Mrad M, Klai S, Mansour M, Nsiri B, Gritli N, et al. Methylenetetrahydrofolate reductase (C677T and A1298C) polymorphisms, hyperhomocysteinemia, and ischemic stroke in Tunisian patients. J Stroke Cerebrovasc Dis 2013;22:465-9.
Settin A, El-Baz R, Ismaeel A, Tolba W, Allah WA. Association of ACE and MTHFR genetic polymorphisms with Type 2 diabetes mellitus: Susceptibility and complications. J Renin Angiotensin Aldosterone Sys 2015;16:838-43.
Angeline T, Jeyaraj N, Tsongalis GJ. MTHFR gene polymorphisms, B-vitamins and hyperhomocystinemia in young and middle-aged acute myocardial infarction patients. Exp Mol Pathol 2007;82:227-33.
Wang D, Bai L, Zhai Q, Li Y, Cao M, Hai J, et al. Association of MTHFR C677T and A1298C polymorphisms with the development of Type 2 diabetic nephropathy and their interaction with environmental factors. Int J Clin Exp Pathol 2017;10:3778-85.
Moczulski D, Fojcik H, Zukowska-Szczechowska E, Szydlowska I, Grzeszczak W. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003;18:1535-40.
Nithya K, Isabel W, Angeline T, Priscilla AS, Asirvatham AJ. Assessment of DNA strand breaks and total antioxidant status in Type 2 diabetic patients with and without complications- A case-control study. Asian J Pharm Clin Res 2017;10:430-4.
Majsterek I, Merecz A, Sliwinska A, Kosmalski M, Kasznicki J, Drzewoski J. Role of oxidative DNA damage in pathogenesis of diabetic neuropathy. World academy of science, engineering and technology. Int J Med Health Biomed Bioeng Pharm Eng 2012;6:494-501.
Rytter E, Vessby B, Asgård R, Johansson C, Sjödin A, Abramsson- Zetterberg L, et al. Glycaemic status in relation to oxidative stress and inflammation in well-controlled Type 2 diabetes subjects. Br J Nutr 2009;101:1423-6.
El Hajj Chehadeh SW, Jelinek HF, Al Mahmeed WA, Tay GK, Odama UO, Elghazali GE, et al. Relationship between MTHFR C677T and A1298C gene polymorphisms and complications of Type 2 diabetes mellitus in an Emirati population. Meta Gene 2016;9:70-5.
Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, et al. Association between polymorphisms of folate-and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001;97:3205-9.
Peres NP, Galbiatti-Dias AL, Castanhole-Nunes MM, da Silva RF, Pavarino ÉC, Goloni-Bertollo EM, et al. Polymorphisms of folate metabolism genes in patients with Cirrhosis and hepatocellular carcinoma. World J Hepatol 2016;8:1234-43.
Tetik Vardarlı A, Zengi A, Bozok Çetintaş V, Karadeniz M, Tamsel S, Küçükaslan AŞ, et al. An association study between gene polymorphisms of folic acid metabolism enzymes and biochemical and hormonal parameters in acromegaly. Genet Test Mol Biomarkers 2015;19:431-8.
Fowdar JY, Lason MV, Szvetko AL, Lea RA, Griffiths LR. Investigation of homocysteine-pathway-related variants in essential hypertension. Int J Hypertens 2012;2012:190923.
Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, Skibola CF, et al. Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood 2010;115:3923-9.
Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007;75:99-106.
Scala I, Granese B, Sellitto M, Salomè S, Sammartino A, Pepe A, et al. Analysis of seven maternal polymorphisms of genes involved in homocysteine/folate metabolism and risk of down syndrome offspring. Genet Med 2006;8:409-16.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
